Can a Two-Pill combo calm the Gut's inflammatory fire?

NCT ID NCT07767370

NEW Recruiting now Disease control Sponsor: The Second Hospital of Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial explores whether adding two experimental capsules, ND-12 and H-6, to standard mesalazine treatment can better control chronic inflammatory diarrhea in adults, including those with active ulcerative colitis. Participants will take the combination or a placebo for 14 days. The study measures changes in a stool marker of gut inflammation (fecal calprotectin) and tracks how many people achieve a meaningful clinical response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ND-12 and H-6 capsules combined with mesalazine
What this could lead to: If it works, this combination could offer a new way to reduce gut inflammation and improve symptoms for people with chronic inflammatory diarrhea.
What could go wrong: This is a very early, small trial, so results may not hold up in larger studies. The treatment could also cause side effects or fail to outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIARRHEA CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic diarrheal disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIARRHEA CHRONIC UC - ULCERATIVE COLITIS

Contacts and locations

Locations

The Second Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.